| 王雨阳,何敏媚.国外创新药纳入医保目录机制研究以及对我国的启示[J].中国药事,2023,(7):834-842 |
| 国外创新药纳入医保目录机制研究以及对我国的启示 |
| Research on the Mechanism of Foreign Inclusion of Innovative Drugs in the List of Medical Insurance and its Implications for China |
| 投稿时间：2022-12-03 |
| DOI：10.16153/j.1002-7777.2023.07.013 |
| 中文关键词: 创新药 医保准入 国际经验 医保药品目录 药物经济学 |
| 英文关键词: innovative medicine medical insurance access international experience catalogue of medical insurance drugs pharmacoeconomics |
| 基金项目: |
|
| 摘要点击次数: 615 |
| 全文下载次数: 373 |
| 中文摘要: |
| 目的：从创新药纳入医保机制的典型国家案例中，汲取能够为我国医保目录管理工作提供思路的借鉴点，为加快创新药物医保准入，建立行之有效、符合国情的医保目录管理体系提出建议。方法：对德国、日本、美国和新西兰4个典型国家的创新药医保目录纳入机制进行纵向案例介绍，再从企业参与程度、价值评估机制、药品定价标准以及动态调整周期4个方面进行横向总结对比，分析其模式中创新及可借鉴之处。结果：4个典型国家在此方面已经具有相对成熟的流程与丰富的经验，并且已经形成一套相对完备且各具特色的体系，对我国有借鉴意义。结论：建议建立健全创新药准入机制，以保证企业充分参与创新药准入全程，建立公平权威的创新药评估机制，选取科学合理的创新药定价标准，实施动态长效的目录调整周期。 |
| 英文摘要: |
| Objective: To draw reference points that could provide ideas for the management of medical insurance catalogue in China, from typical countries cases of innovative drugs being incorporated into medical insurance mechanism, to give advice on accelerating the access of innovative drugs, and put forward suggestions for establishing an eff ective medical insurance catalogue management system in line with the Chinese conditions. Methods: The inclusion mechanism of innovative drugs medical insurance list in four typical countries, Germany, Japan, the United States and New Zealand was introduced in a longitudinal way, and the participation of enterprise, the value evaluation mechanism, the drug pricing mode and dynamic adjustment cycle in four aspects were summarized and compared in a horizontal way, so as to analyze the innovations and reference points from the model. Results: Four typical countries have already equipped a relatively mature processes and experience, and a set of relatively complete and distinctive system has been formed, which has the reference signifi cance to our country. Conclusion: To establish and improve an innovative drug access mechanism, we need to ensure that enterprises fully participate in the whole process of innovative drug access, establish a fair and authoritative innovative drug evaluation mechanism, select a scientifi c and reasonable innovative drug pricing standard, and implement a dynamic long-term catalogue adjustment cycle. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|